Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Condition: Advanced Breast Cancer Interventions: Drug: The combination of Dalpiciclib with physician-selected endocrine therapy; Drug: Chemotherapy selected by the physician Sponsors: Peking Union Medical College Hospital; Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials